• 1
    Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998; 157: 351370.
  • 2
    Soderling SH, Beavo JA. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 2000; 12: 174179.
  • 3
    Torphy TJ, Page C. Phosphodiesterases: the journey toward therapeutics. Trends Pharmacol Sci 2000; 21: 157159.
  • 4
    Brunnee T, Engelstatter R, Steinijans VW, Kunkel G. Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma. Eur Respir J 1992; 5: 982985.
  • 5
    Fujimura M, Kamio Y, Saito M, Hashimoto T, Matsuda T. Bronchodilator and bronchoprotective effects of cilostazol in humans in vivo. Am J Respir Crit Care Med 1995; 151: 222225.
  • 6
    Foster RW, Rakshi K, Carpenter JR, Small RC. Trials of the bronchodilator activity of the isoenzyme-selective phosphodiesterase inhibitor AH 21–132 in healthy volunteers during a methacholine challenge test. Br J Clin Pharmacol 1992; 34: 527534.
  • 7
    Kawasaki A, Hoshino K, Osaki R, Mizushima Y, Yano S. Effect of ibudilast: a novel antiasthmatic agent, on airway hypersensitivity in bronchial asthma. J Asthma 1992; 29: 245252.
  • 8
    Bardin PG, Dorward MA, Lampe FC, Franke B, Holgate ST. Effect of selective phosphodiesterase 3 inhibition on the early and late asthmatic responses to inhaled allergen. Br J Clin Pharmacol 1998; 45: 387391.
  • 9
    Harbinson PL, MacLeod D, Hawksworth R, et al. The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur Respir J 1997; 10: 10081014.
  • 10
    Nell H, Louw C, Leichtl S, Rathgeb F, et al. Acute anti-inflammatory effect of the novel phosphodiesterase 4 inhibitor roflumilast on allergen challenge in asthmatics after a single dose. Am J Respir Crit Care Med 2000; 161: A200.
  • 11
    Jonker GJ, Tijhuis GJ De Monchey JGR. RP 73401 (a phosphodiesterase IV inhibitor) single does not prevent allergen induced bronchoconstriction during the early phase reaction in asthmatics. Eur Respir J 1996; 9: 82s.
  • 12
    Nieman RB Fisher BD Amit O Dockhorn RJ. SB 207499 (ArifloTM), a second-generation, selective oral phosphodiesterase type 4 (PDE4) inhibitor, attenuates exercise induced bronchoconstriction in patients with asthma. Am J Respir Crit Care Med 1998; 157: A413.
  • 13
    Timmer W, Leclerc V, Birraux G, et al. Safety and efficacy of the new PDE4 inhibitor roflumilast administered to patients with excercise-induced asthma over 4 weeks. Am J Respir Crit Care Med 2000; 161: A505.
  • 14
    Torphy TJ, Barnette MS, Underwood DC, et al. ArifloTM (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD. from concept to clinic. Pulm Pharmacol Ther 1999; 12: 131135.
  • 15
    Gale DD, Hofer P, Spina D, et al. The pharmacology of a novel phosphodiesterase type 4 inhibitor, V11294A. Pulm Pharmacol Ther 2002; (in press).
  • 16
    Spina D, Landells LJ, Page CP. The role of phosphodiesterase isoenzymes in health and in atopic disease. In Advances in Pharmacology, ed. AugustT. San Diego: Academic Press Inc, 1998: 3389.